Abstract
Advances in mass-spectrometry(MS)-based technologies have leveraged our understanding of skeletal muscle responsiveness to exercise in humans. However, there is a lack of such data in females, particularly pertaining to female athletes and menstrual cycle phase-based sprint interval training(SIT) despite its efficacy and popularity. Here, we present a comprehensive proteomic analysis of skeletal muscle adaptations to high-frequency SIT during different menstrual cycle phases in female athletes. We randomized 49 eumenorrheic females to either high-frequency SIT in the follicular(FB) or luteal phase(LB) over one menstrual cycle comprising eight sessions of 6×30-s all-out efforts. Twenty-five completed the intervention with verified cycles. MS-based proteomics revealed notable differences in muscle adaptations to phase-based SIT. LB suppressed mitochondrial pathways of the tricarboxylic acid cycle and electron transport chain while enriching ribosomal complexes. Conversely, FB enriched filament organization and skeletal system development. Mitochondrial repression during LB was linked to reduced V̇O2max, whereas exercise capacity improved in FB only. Our findings show that synching high-frequency SIT with menstrual cycle phases induces distinct muscle adaptations and affects phenotype in eumenorrheic female athletes.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04136457
Funding Statement
The study was supported as part of the Novo Nordisk Foundation grant to Team Danmark to the research network "Training strategies and competition preparation". Mass spectrometry analyses: supported by the Novo Nordisk Foundation (NNF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the regional ethics committee of Copenhagen, Denmark (H-20052639).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE(Perez-Riverol et al., 2022) partner repository with the dataset identifier PXD051852.
